糖痹消治疗糖尿病周围神经病变临床疗效观察
发布时间:2018-12-23 08:04
【摘要】:目的:本试验研究旨在观察临床经验方糖痹消在治疗糖尿病周围神经病变的有效性和安全性,为糖尿病周围神经病变的治疗提供临床依据。材料与方法:选取60例营口市中医院糖尿病门诊患者,确诊为糖尿病周围神经病变,且依据《糖尿病中医防治指南》辨证属气虚血瘀证型。将患者分为试验组与对照组,其中试验组30例,对照组30例。试验组给予基础降糖治疗联合糖痹消水煎剂100ml日三次口服;对照组给予基础降糖治疗联合甲钴胺胶囊0.5mg日三次口服,疗程四周,观察试验组和对照组的中医证候积分,Toronto积分,血脂,血糖的变化。结果:1.治疗结束后,两组Toronto积分间疗效的综合比较,试验组的总有效率90%,对照组的总有效率为73.33%,两组比较有显著性差异,结果具有统计学意义(P0.05),试验组优于对照组。2.治疗结束后,两组中医证候积分疗效的综合比较,试验组的总有效率为86.67%,对照组的总有效率为63.33%,两组相比,差异显著。结果具有统计学意义(P0.05),试验组优于对照组。3.两组Toronto积分比较,两组较治疗前有改善,差异具有统计学意义(P0.05),治疗后试验组与对照组比较,差异显著(P0.05)。4.两组中医症状积分比较,两组较治疗前有改善,差异具有统计学意义(P0.05),治疗后试验组与对照组比较,存在明显差异(P0.05)。5.治疗结束后,试验组和对照组在空腹血糖、餐后两小时血糖、血脂方面无明显差异(P0.05)。6.治疗结束后,在ALT,AST,尿素,肌酐方面,试验组和对照组无统计学差异(P0.05)。结论:1.“糖痹消复方”能够有效改善糖尿病周围神经病变患者的临床症状,降低糖尿病患者的周围神经病变Toronto评分和中医证候积分,且安全性良好。
[Abstract]:Objective: to observe the efficacy and safety of Fangtang Bixiao in the treatment of diabetic peripheral neuropathy and to provide clinical basis for the treatment of diabetic peripheral neuropathy. Materials and methods: 60 patients with diabetes mellitus in Yingkou traditional Chinese Medicine Hospital were diagnosed as diabetic peripheral neuropathy, and according to the guidelines for the Prevention and treatment of Diabetes in TCM, the syndrome differentiation belonged to qi deficiency and blood stasis syndrome. The patients were divided into experimental group (30 cases) and control group (30 cases). The experimental group was given basic hypoglycemic therapy combined with Tangbixiao decoction 100ml three times a day oral; The control group was given basic hypoglycemic therapy combined with megalobalamin capsule 0.5mg three times a day for four weeks. The changes of TCM syndrome score, Toronto score, blood lipid and blood glucose were observed in the experimental group and the control group. Results: 1. After the treatment, the total effective rate of the experimental group was 90, and the total effective rate of the control group was 73.33. There was a significant difference between the two groups, the results were statistically significant (P0.05). The experimental group was superior to the control group. 2. After the treatment, the total effective rate of the experimental group was 86.67 and that of the control group was 63.333.The difference between the two groups was significant. The results were statistically significant (P0.05). The experimental group was better than the control group. Compared with the two groups, the Toronto scores of the two groups were improved, the difference was statistically significant (P0.05), and the difference between the experimental group and the control group was significant (P0.05) after treatment (P0.05). Two groups of TCM symptom scores, the two groups were improved before treatment, the difference was statistically significant (P0.05), after treatment, there was a significant difference between the experimental group and the control group (P0.05). After treatment, there was no significant difference in fasting blood glucose, 2 hours postprandial blood glucose and blood lipid between the experimental group and the control group (P0.05). After treatment, there was no significant difference in ALT,AST, urea and creatinine between the test group and the control group (P0.05). Conclusion: 1. "Tangbixiao compound" can effectively improve the clinical symptoms of patients with diabetic peripheral neuropathy, reduce the Toronto score and TCM syndromes score of diabetic patients with peripheral neuropathy, and the safety is good.
【学位授予单位】:辽宁中医药大学
【学位级别】:硕士
【学位授予年份】:2017
【分类号】:R259;R277.7
本文编号:2389664
[Abstract]:Objective: to observe the efficacy and safety of Fangtang Bixiao in the treatment of diabetic peripheral neuropathy and to provide clinical basis for the treatment of diabetic peripheral neuropathy. Materials and methods: 60 patients with diabetes mellitus in Yingkou traditional Chinese Medicine Hospital were diagnosed as diabetic peripheral neuropathy, and according to the guidelines for the Prevention and treatment of Diabetes in TCM, the syndrome differentiation belonged to qi deficiency and blood stasis syndrome. The patients were divided into experimental group (30 cases) and control group (30 cases). The experimental group was given basic hypoglycemic therapy combined with Tangbixiao decoction 100ml three times a day oral; The control group was given basic hypoglycemic therapy combined with megalobalamin capsule 0.5mg three times a day for four weeks. The changes of TCM syndrome score, Toronto score, blood lipid and blood glucose were observed in the experimental group and the control group. Results: 1. After the treatment, the total effective rate of the experimental group was 90, and the total effective rate of the control group was 73.33. There was a significant difference between the two groups, the results were statistically significant (P0.05). The experimental group was superior to the control group. 2. After the treatment, the total effective rate of the experimental group was 86.67 and that of the control group was 63.333.The difference between the two groups was significant. The results were statistically significant (P0.05). The experimental group was better than the control group. Compared with the two groups, the Toronto scores of the two groups were improved, the difference was statistically significant (P0.05), and the difference between the experimental group and the control group was significant (P0.05) after treatment (P0.05). Two groups of TCM symptom scores, the two groups were improved before treatment, the difference was statistically significant (P0.05), after treatment, there was a significant difference between the experimental group and the control group (P0.05). After treatment, there was no significant difference in fasting blood glucose, 2 hours postprandial blood glucose and blood lipid between the experimental group and the control group (P0.05). After treatment, there was no significant difference in ALT,AST, urea and creatinine between the test group and the control group (P0.05). Conclusion: 1. "Tangbixiao compound" can effectively improve the clinical symptoms of patients with diabetic peripheral neuropathy, reduce the Toronto score and TCM syndromes score of diabetic patients with peripheral neuropathy, and the safety is good.
【学位授予单位】:辽宁中医药大学
【学位级别】:硕士
【学位授予年份】:2017
【分类号】:R259;R277.7
【参考文献】
相关期刊论文 前10条
1 邓雅婷;李竞;;糖尿病周围神经病变综合性治疗进展[J];中国药师;2017年02期
2 周昊玲;颜灿群;;糖尿病周围神经病变的研究进展[J];西南军医;2017年01期
3 刘爽;;黄芪药理作用的研究进展[J];北方药学;2015年12期
4 赵秋艳;;川芎鉴定及临床应用分析[J];中国卫生标准管理;2015年09期
5 黄庆勇;李煌;许文;徐伟;张玉琴;褚克丹;陈娴雯;谢施恩;;君药天花粉对复方栝楼桂枝汤中9种成分的影响[J];中国实验方剂学杂志;2014年12期
6 陆祖谦;丁维;;糖尿病周围神经病变诊治进展[J];药品评价;2013年17期
7 付庆林;饶高峰;;甲钴胺联合前列地尔治疗2型糖尿病周围神经病变的疗效与安全性[J];中国临床药理学杂志;2012年07期
8 谢宝强;周青美;;甲钴胺与法舒地尔联合治疗糖尿病周围神经病变的疗效[J];中国老年学杂志;2012年05期
9 施君;张文川;;糖尿病周围神经病变发病机制的研究进展[J];上海交通大学学报(医学版);2012年01期
10 庞国明;闫镛;郑晓东;;糖尿病周围神经病变中医防治指南[J];中国中医药现代远程教育;2011年22期
,本文编号:2389664
本文链接:https://www.wllwen.com/zhongyixuelunwen/2389664.html
最近更新
教材专著